The Impact on Compounded Tirzepatide During the shortage, compounding pharmacies stepped in to fill the gap by producing off-brand versions of tirzepatide
The scientists found that between 2017 and 2022: Average total payments per patient increased 157% among adults without diabetes and 36% among those with diabetes Despite rising total payments, average out-of-pocket payments per patient declined 26% among adults without diabetes and 39% among those with diabetes GLP-1 use increased 643% among adults without diabetes and 230% among adults with diabetes Semaglutide became the dominant GLP-1 drug by 2022, accounting for 54% of usage among adults with diabetes and 65% among adults without diabetes The authors note that while this study only used data through 2022, Medicare and Medicaid spending on GLP-1s has continued to surge in recent years
Notably, Ozempic (semaglutide) has not been studied in pregnant people, and a phenomenon of Ozempic babies has arisen
Poison centers at CHOP and Rutgers are seeing an increase, too
Electrospray tandem mass spectrometry for analysis of acylcarnitines in dried postmortem blood specimens collected at autopsy from infants with unexplained cause of death
Read more: No, taking drugs like Ozempic isnt cheating at weight loss or the easy way out How can you avoid gaining weight when you stop